Immune checkpoint inhibitors (ICIs) to programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) can activate antitumor immunity and mediate cancer recession [6]. The gene discussed is CTLA4; the disease is cancer.